Whether that peptide is ever actually cleaved and released as an independent signaling molecule in living tissue is one of the fields genuinely unresolved questions, discussed in the limitations section below
Yet in April 2024, the smaller LIXIPARK trial had shown the opposite, with lixisenatide slowing motor decline in early Parkinsons disease over 12 months [3]
We would suggest starting your injection wherever you feel most comfortable
Current GLP-1 analogues approved for use in the United States and the European Union include: exenatide twice daily [4], exenatide once weekly [5], liraglutide once daily [6], lixisenatide once daily (not approved in the U.S.) [7] and albiglutide once weekly [8], which are all delivered through subcutaneous injection and initial dose titration is required to improve gastrointestinal tolerance
This includes disclosing the prices charged by pharmaceutical manufacturers, wholesalers, and other intermediaries involved in the supply chain